These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20588171)

  • 1. Expanding access to HAART: a cost-effective approach for treating and preventing HIV.
    Johnston KM; Levy AR; Lima VD; Hogg RS; Tyndall MW; Gustafson P; Briggs A; Montaner JS
    AIDS; 2010 Jul; 24(12):1929-35. PubMed ID: 20588171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.
    Lima VD; Hogg RS; Montaner JS
    PLoS One; 2010 Jun; 5(6):e10991. PubMed ID: 20539817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
    Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
    Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.
    Nosyk B; Montaner JS; Yip B; Lima VD; Hogg RS;
    Med Care; 2014 Apr; 52(4):362-9. PubMed ID: 24848208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.
    Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD
    J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.
    Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG
    Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study.
    Nosyk B; Lima V; Colley G; Yip B; Hogg RS; Montaner JS
    Pharmacoeconomics; 2015 Mar; 33(3):243-53. PubMed ID: 25404425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
    Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
    Zang X; Tang H; Min JE; Gu D; Montaner JS; Wu Z; Nosyk B
    PLoS One; 2016; 11(11):e0167308. PubMed ID: 27893864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013.
    Nosyk B; Min JE; Krebs E; Zang X; Compton M; Gustafson R; Barrios R; Montaner JSG;
    Clin Infect Dis; 2018 Feb; 66(5):765-777. PubMed ID: 29028964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of HAART for adults with HIV in England.
    Miners AH; Sabin CA; Trueman P; Youle M; Mocroft A; Johnson M; Beck EJ
    HIV Med; 2001 Jan; 2(1):52-8. PubMed ID: 11737376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.